Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Guardant Health, Inc.    GH

GUARDANT HEALTH, INC.

(GH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Guardant Health, Inc. : The upward trend should continue

share with twitter share with LinkedIn share with facebook
07/30/2020 | 08:04am EDT
long trade
Stop-loss triggered
Entry price : 83.02$ | Target : 93$ | Stop-loss : 80.6$ | Potential : 12.02%
Guardant Health, Inc. shares have recently experienced an upward movement with a return of higher volumes and volatility. This technical chart pattern suggests a continuation of the upward movement.
Investors have an opportunity to buy the stock and target the $ 93.
Guardant Health, Inc. : Guardant Health, Inc. : The upward trend should continue
Strengths
  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • The group usually releases upbeat results with huge surprise rates.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 76.19 USD

Weaknesses
  • The company has insufficient levels of profitability.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.

Gallien Girardot
© MarketScreener.com 2020
share with twitter share with LinkedIn share with facebook

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (USD)
Sales 2020 278 M - -
Net income 2020 -151 M - -
Net Debt 2020 - - -
P/E ratio 2020 -55,3x
Yield 2020 -
Capitalization 8 512 M 8 512 M -
Capi. / Sales 2020 30,7x
Capi. / Sales 2021 22,9x
Nbr of Employees 622
Free-Float 90,3%
Upcoming event on GUARDANT HEALTH, INC.
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Average target price 111,25 $
Last Close Price 85,61 $
Spread / Highest target 51,9%
Spread / Average Target 29,9%
Spread / Lowest Target 5,13%
EPS Revisions
Managers
NameTitle
Helmy Eltoukhy Chief Executive Officer & Director
AmrAli H. Talasaz Chairman, President & Chief Operations Officer
Derek A. Bertocci Chief Financial Officer
Kumud Kalia Chief Information Officer
Darya Chudova Senior Vice President-Technology
Sector and Competitors